Zobrazeno 1 - 10
of 2 456
pro vyhledávání: '"H., Goldschmidt"'
Autor:
Jerome H. Goldschmidt, Wan-Yu Tseng, Yunfei Wang, Janet Espirito, Anupama Vasudevan, Michelle Silver, Jackie Kwong, Ruchit Shah, Elizabeth Marrett
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 425-439 (2024)
Abstract Background For patients with metastatic non-small cell lung cancer, timely molecular testing is essential to determine the appropriate course of therapy. Initial treatment with platinum chemotherapy and/or an immune checkpoint inhibitor (ICI
Externí odkaz:
https://doaj.org/article/06bccd3f99814b6fa7f9c8888da41661
Autor:
Jerome H. Goldschmidt, Lin‐Na Chou, Philip K. Chan, Liwei Chen, Nicholas Robert, Joyce Kinsey, Katherine Pitts, Matt Nestor, Edwin P. Rock, Hillard M. Lazarus
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20783-20797 (2023)
Abstract Background Patient survival in advanced/metastatic melanoma, non‐small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) has improved with immune checkpoint inhibitors (ICI). Biomarkers' role in prognosis and treatment has been limi
Externí odkaz:
https://doaj.org/article/bcd408a5dd8c4136bb20c543a07474f6
Autor:
Shirish M. Gadgeel, Pragya Rai, Srinivas Annavarapu, Sartaj Alam, Jerome H. Goldschmidt, Howard (Jack) West, Melissa Santorelli, Renata Eiras Martins
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis study investigated real-world time on treatment (rwToT) and overall survival (OS) for patients with metastatic non-small cell lung cancer (mNSCLC) who initiated first-line (1L) pembrolizumab monotherapy. We also explored discontinuatio
Externí odkaz:
https://doaj.org/article/9b3a9a0770cd434b8b46c82596f9dd6b
Autor:
U. Dapunt, T. Nonnenmacher, S. Zschäbitz, M. Burghardt, M. Hajiyianni, E.K. Mai, M.S. Raab, C. Müller-Tidow, H.U. Kauczor, H. Goldschmidt, T.D. Do
Publikováno v:
Brain and Spine, Vol 4, Iss , Pp 104010- (2024)
Externí odkaz:
https://doaj.org/article/d67e31d9967d43d6bbac66b0c11b8211
Autor:
Ran Jin, Adesuwa S. Ogbomo, Neil A. Accortt, Lincy S. Lal, Geetanjali Bishi, Darcie Sandschafer, Jerome H. Goldschmidt
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Bevacizumab-awwb (MVASI ® ) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin ® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC)
Externí odkaz:
https://doaj.org/article/1e3bd947becc4f728269150e570d3bc4
Autor:
K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani
Publikováno v:
HemaSphere, Vol 7, Iss S2, Pp 14-15 (2023)
Externí odkaz:
https://doaj.org/article/38f179d91cdc4e74852dbdd8453e5e98
Autor:
ME Agha, AD Cohen, D Madduri, YC Cohen, M Delforge, J Hillengass, H Goldschmidt, K Weisel, M Raab, C Scheid, JM Schecter, KC Braganca, H Varsos, L Wang, M Vogel, MJ Carrasco-Alfonso, M Akram, X Wu, T Nesheiwat, H Einsele
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S255- (2021)
Objectives: Cilta-cel is a CAR-T cell therapy that expresses 2 BCMA-targeting single-domain antibodies, designed to confer avidity. In the multicohort, phase 2 CARTITUDE-2 study (NCT04133636), the safety and efficacy of cilta-cel in various clinical
Externí odkaz:
https://doaj.org/article/ed76fbe5040642cf9353385b1597d847
Autor:
N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, A. Chari
Publikováno v:
HemaSphere, Vol 6, Pp 84-85 (2022)
Externí odkaz:
https://doaj.org/article/1a178de35dce4f698e3fa5372da5721d
Autor:
S. Huhn, A. M. Poos, E. K. Mai, M. Hänel, H. J. Salwender, J. Dürig, I. W. Blau, C. Scheid, K. C. Weisel, M. Munder, O. Berlanga, U. Bertsch, H. Goldschmidt, N. Weinhold
Publikováno v:
HemaSphere, Vol 6, Pp 771-772 (2022)
Externí odkaz:
https://doaj.org/article/402d78268cb74960ad8fc2340e8cbae1
Autor:
K. Weisel, A. Chari, S. Z. Usmani, H. Goldschmidt, M.-V. Mateos, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, P. Moreau
Publikováno v:
HemaSphere, Vol 6, Pp 862-863 (2022)
Externí odkaz:
https://doaj.org/article/3baafcb582854c9e8b410ee65630dc20